Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
Risk and Volatility
Tectonic Therapeutic has a beta of 3.26, suggesting that its stock price is 226% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Profitability
This table compares Tectonic Therapeutic and Invivyd’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -30.13% | -27.52% |
| Invivyd | -389.01% | -165.24% | -99.71% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | -$57.98 million | ($7.31) | -2.58 |
| Invivyd | $25.38 million | 3.26 | -$169.93 million | ($1.20) | -0.58 |
Tectonic Therapeutic has higher earnings, but lower revenue than Invivyd. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 25.4% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Tectonic Therapeutic and Invivyd, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 6 | 2 | 3.25 |
| Invivyd | 0 | 0 | 3 | 1 | 3.25 |
Tectonic Therapeutic currently has a consensus price target of $82.33, suggesting a potential upside of 337.01%. Invivyd has a consensus price target of $5.85, suggesting a potential upside of 747.83%. Given Invivyd’s higher probable upside, analysts clearly believe Invivyd is more favorable than Tectonic Therapeutic.
Summary
Tectonic Therapeutic beats Invivyd on 7 of the 13 factors compared between the two stocks.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
